Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name EO2401
Trade Name
Synonyms EO 2401|EO-2401
Drug Descriptions

EO2401 is a cancer vaccine comprising microbiome-derived peptides that are similar to IL13Ralpha2, BIRC5, and FOXM1, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2034-2034).

CAS Registry Number NA
NCIT ID C16564


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Bevacizumab + EO2401 + Nivolumab Bevacizumab EO2401 Nivolumab 0 0
EO2401 EO2401 0 1
EO2401 + Nivolumab EO2401 Nivolumab 0 1

Additional content available in CKB BOOST